Secondly, for leukemia, medically, the causes of leukemia can be divided into congenital and acquired. Acquired leukemia can be completely treated with autologous cord blood; However, congenital diseases cannot be treated with autologous cord blood because of their own genetic defects, and only other people's cord blood can be used. If the patient has leukemia within 1 year, congenital genetic factors are usually considered in clinic. Autologous umbilical cord blood transplantation is not used to treat congenital leukemia because it cannot correct its genetic defects. However, clinical data show that the incidence of congenital leukemia is only 5%.
If leukemia is not congenital, autologous umbilical cord blood transplantation has great advantages over stem cell transplantation from other sources (bone marrow and peripheral blood), especially allogeneic stem cells. Because there is almost no transplant rejection problem in autologous umbilical cord blood transplantation, there is basically no transplant failure.
In addition, because it is autologous cell, there will be no graft-versus-host disease reaction, so autologous umbilical cord blood transplantation is relatively safe. Especially for severe aplastic anemia, some solid tumors and leukemia, rehabilitation can be achieved by autologous cord blood transplantation. There have been many healthy treatment cases here, and the rehabilitation effect is better than that of allogeneic, and the cost is much less.